Document ID: chunk:federal_register_of_legislation:C2025C00090:section:99adh:p3
Version: federal_register_of_legislation:C2025C00090
Segment Type: section
Provision Reference: s 99ADH (pt 3/3)
Character Range: 398289–399801

brand of the pharmaceutical item in relation to any of those data collection periods; and
 (c) those data collection periods include the data collection period mentioned in paragraph (1)(a).
Example: The 12.5% average unadjusted price reduction test was passed using data from the data collection periods ending on 30 September 2022, 31 March 2023 and 30 September 2023. A price reduction occurred on 1 April 2024. The next reduction day for which the 12.5% average unadjusted price reduction test could be passed would be 1 October 2025, using data from the data collection periods ending on 31 March 2024, 30 September 2024 and 31 March 2025.
 (7) For the purposes of subsection (6), if the Minister determines the weighted average disclosed price of a brand of a pharmaceutical item in respect of a data collection period for the brand, the unadjusted price reduction for the brand of the pharmaceutical item in respect of the data collection period is the unadjusted price reduction for the brand of the pharmaceutical item when the determination came into force.
Note: See subsection 99ADB(4).
 (8) For the purposes of paragraph (6)(b), this section did not apply to the brand of the pharmaceutical item in relation to any of those data collection periods if the approved ex‑manufacturer price of the brand of the pharmaceutical item had not been reduced under subsection (3) as a result of calculations using data from any of those 3 data collection periods.
 (9) Subsection (8) is included to avoid doubt.